OpGen, Inc. (OPGN)
USD 3.36
(0.3%)
USD 3.36
(0.3%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 11.89 Million USD | 60.72% |
| 2022 | 7.39 Million USD | 167.87% |
| 2021 | -10.9 Million USD | -214.9% |
| 2020 | 9.48 Million USD | 2000.15% |
| 2019 | 451.76 Thousand USD | 116.88% |
| 2018 | -2.67 Million USD | -385.66% |
| 2017 | -551.21 Thousand USD | 80.05% |
| 2016 | -2.76 Million USD | 55.33% |
| 2015 | -6.18 Million USD | -348.36% |
| 2014 | 2.49 Million USD | 337.2% |
| 2013 | -1.04 Million USD | 85.25% |
| 2012 | -7.11 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 13.3 Million USD | 4.01% |
| 2024 Q1 | 12.78 Million USD | 7.54% |
| 2023 Q1 | 6.9 Million USD | -6.69% |
| 2023 Q3 | 12.25 Million USD | 29.59% |
| 2023 Q4 | 11.89 Million USD | -3.0% |
| 2023 Q2 | 9.46 Million USD | 37.04% |
| 2023 FY | 11.89 Million USD | 60.72% |
| 2022 Q3 | 5.16 Million USD | 253.74% |
| 2022 Q1 | -4.96 Million USD | 54.45% |
| 2022 FY | 7.39 Million USD | 167.87% |
| 2022 Q4 | 7.39 Million USD | 43.34% |
| 2022 Q2 | 1.45 Million USD | 129.39% |
| 2021 Q1 | -15.88 Million USD | -267.43% |
| 2021 Q2 | -6.61 Million USD | 58.38% |
| 2021 FY | -10.9 Million USD | -214.9% |
| 2021 Q3 | -558.96 Thousand USD | 91.54% |
| 2021 Q4 | -10.9 Million USD | -1850.23% |
| 2020 FY | 9.48 Million USD | 2000.15% |
| 2020 Q3 | 10.94 Million USD | 38.45% |
| 2020 Q2 | 7.9 Million USD | 188.98% |
| 2020 Q1 | -8.88 Million USD | -2067.4% |
| 2020 Q4 | 9.48 Million USD | -13.35% |
| 2019 Q3 | 3.05 Million USD | 296.55% |
| 2019 FY | 451.76 Thousand USD | 116.88% |
| 2019 Q4 | 451.76 Thousand USD | -85.19% |
| 2019 Q2 | 769.14 Thousand USD | 139.01% |
| 2019 Q1 | -1.97 Million USD | 26.36% |
| 2018 Q3 | -2.77 Million USD | 49.33% |
| 2018 Q4 | -2.67 Million USD | 3.5% |
| 2018 FY | -2.67 Million USD | -385.66% |
| 2018 Q1 | -8.81 Million USD | -1498.55% |
| 2018 Q2 | -5.47 Million USD | 37.87% |
| 2017 FY | -551.21 Thousand USD | 80.05% |
| 2017 Q3 | -3.47 Million USD | -296.87% |
| 2017 Q2 | 1.76 Million USD | 548.86% |
| 2017 Q4 | -551.21 Thousand USD | 84.13% |
| 2017 Q1 | -393.11 Thousand USD | 85.77% |
| 2016 Q1 | -2.45 Million USD | 60.33% |
| 2016 Q3 | -2.76 Million USD | 56.69% |
| 2016 Q2 | -6.39 Million USD | -160.55% |
| 2016 FY | -2.76 Million USD | 55.33% |
| 2016 Q4 | -2.76 Million USD | 0.22% |
| 2015 FY | -6.18 Million USD | -348.36% |
| 2015 Q4 | -6.18 Million USD | 35.85% |
| 2015 Q2 | -9.88 Million USD | -413.0% |
| 2015 Q3 | -9.64 Million USD | 2.46% |
| 2015 Q1 | 3.15 Million USD | 26.81% |
| 2014 FY | 2.49 Million USD | 337.2% |
| 2014 Q4 | 2.49 Million USD | 152.9% |
| 2014 Q1 | 1.4 Million USD | 221.16% |
| 2014 Q3 | 984.63 Thousand USD | 0.0% |
| 2013 Q4 | -1.15 Million USD | 0.0% |
| 2013 FY | -1.04 Million USD | 85.25% |
| 2012 FY | -7.11 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 130.143% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 301.079% |
| Aspira Women's Health Inc. | -331 Thousand USD | 3692.714% |
| Biodesix, Inc. | 34.3 Million USD | 65.337% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 305.176% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 1056.761% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 1056.761% |
| Bionano Genomics, Inc. | 34.88 Million USD | 65.908% |
| CareDx, Inc | -47.97 Million USD | 124.787% |
| Check-Cap Ltd. | -24.75 Million USD | 148.036% |
| Castle Biosciences, Inc. | -83.53 Million USD | 114.236% |
| DarioHealth Corp. | -7.54 Million USD | 257.55% |
| Exact Sciences Corporation | 1.94 Billion USD | 99.39% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 114.403% |
| Guardant Health, Inc. | 220.22 Million USD | 94.6% |
| ICON Public Limited Company | 3.56 Billion USD | 99.666% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 97.592% |
| Illumina, Inc. | 1.21 Billion USD | 99.02% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 318.896% |
| iSpecimen Inc. | -2.14 Million USD | 653.775% |
| Standard BioTools Inc. | 46.5 Million USD | 74.429% |
| MDxHealth SA | 18.88 Million USD | 37.03% |
| 23andMe Holding Co. | -141.37 Million USD | 108.412% |
| Medpace Holdings, Inc. | -103.32 Million USD | 111.509% |
| Myriad Genetics, Inc. | 88.1 Million USD | 86.502% |
| Mainz Biomed B.V. | 349.85 Thousand USD | -3299.089% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 587.471% |
| NeoGenomics, Inc. | 269.19 Million USD | 95.582% |
| Neogen Corporation | 735.62 Million USD | 98.383% |
| Inotiv, Inc. | 382.14 Million USD | 96.888% |
| Natera, Inc. | -200.1 Million USD | 105.943% |
| OPKO Health, Inc. | 230.68 Million USD | 94.845% |
| Psychemedics Corporation | 334 Thousand USD | -3460.444% |
| Prenetics Global Limited | -43.33 Million USD | 127.44% |
| Prenetics Global Limited | -43.33 Million USD | 127.44% |
| Precipio, Inc. | -386 Thousand USD | 3180.799% |
| Personalis, Inc. | -8.02 Million USD | 248.241% |
| RadNet, Inc. | 1.14 Billion USD | 98.965% |
| Sera Prognostics, Inc. | -2.02 Million USD | 688.125% |
| Sotera Health Company | 2.02 Billion USD | 99.413% |
| Neuronetics, Inc. | 2.79 Million USD | -325.166% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 177.537% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 177.537% |
| Trinity Biotech plc | 63.73 Million USD | 81.342% |
| T2 Biosystems, Inc. | 33.8 Million USD | 64.826% |
| Twist Bioscience Corporation | -192.4 Million USD | 106.181% |
| Exagen Inc. | -12.77 Million USD | 193.109% |